Download PDF
Nephrologie aktuell 2023; 27(06): 271-275
DOI: 10.1055/a-2055-3728
Schwerpunkt
Nephrologie

Post-Transplantations-Diabetes mellitus

Häufige Komplikation nach Transplantation
Undine Ott
1   KfH Nierenzentrum Jena, Jena
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

ZUSAMMENFASSUNG

Die Zahl der Transplantationen ist rückläufig. Umso wichtiger ist eine konsequente Nachsorge zur Erhaltung der Transplantatfunktion. Eine häufige Komplikation (10–40 %) ist der Post-Transplantations-Diabetes mellitus (PTDM). Besonders im ersten Jahr ist das Erkrankungsrisiko hoch. Alter, Übergewicht, männliches Geschlecht, eine präexistente Insulinresistenz sowie die immunsuppressive Therapie begünstigen das Auftreten. Der PTDM führt zu hoher kardiovaskulärer Mortalität. Der orale Glukosetoleranztest (oGTT) stellt den Goldstandard der Diagnostik dar. Zusätzlich werden Nüchtern- und Spontanglukose sowie HbA1c herangezogen. Ein postoperativ diagnostizierter PTDM sollte mit Insulin behandelt werden. Eine frühe Intervention verzögert die Entwicklung einer relevanten Glukosestoffwechselstörung häufig über viele Monate. Die therapeutischen Möglichkeiten sind vielfältig und beinhalten neben der Blutzuckereinstellung die Behandlung kardiovaskulärer Risikofaktoren (Hyperlipidämie, Hypertonie). Patientenschulungen sind sinnvoll.



Publication History

Article published online:
20 July 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Starzl TE, Marchioro TL, Rifkind D. et al Factors in successful renal transplantation. Surgery 1964; 56: 296-318
    PubMedSearch in Google Scholar
  • 2 American Diabetes Association. 2 Classification and diagnosis of diabetes: standards of medical care in diabetes – 2019. Diabetes Care. 2019 42. S13-S28
    CrossrefPubMedSearch in Google Scholar
  • 3 Sharif A, Hecking M, de Vries APJ. et al Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant 2014; 14: 1992-2000
    CrossrefPubMedSearch in Google Scholar
  • 4 Langsford D, Dwyer K. Dysglycemia after renal transplantation: definition, pathogenesis, outcomes and implications for management. World J Diabetes 2015; 06: 1132-1151
    CrossrefPubMedSearch in Google Scholar
  • 5 Jahn I, Busch M, Ott U. et al Posttransplantationsdiabetes mellitus bei Patienten nach Nierentransplantation. Dtsch Med Wochenschr 2016; 141: e173-e182
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Grundman JB, Wolfsdorf JI, Marks BE. Post-Transplantation Diabetes Mellitus in Pediatric Patients. Horm Res Paediatr 2020; 93: 510-518
    CrossrefPubMedSearch in Google Scholar
  • 7 Bergrem HA, Valderhaug TG, Hartmann A. et al Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy. Clin J Am Soc Nephrol 2010; 05: 616-622
    CrossrefPubMedSearch in Google Scholar
  • 8 Larosa C, Baluarte HJ, Meyers KE. Outcomes in pediatric solid-organ transplantation. Pediatr Transplant 2011; 15: 128-141
    CrossrefPubMedSearch in Google Scholar
  • 9 Chanchlani R, Kim SJ, Dixon SN. et al Incidence of new-onset diabetes mellitus and association with mortality in childhood solid organ transplant recipients: a population-based study. Nephrol Dial Transplant 2019; 34: 524-31
    CrossrefPubMedSearch in Google Scholar
  • 10 Hjelmesæth J, Hartmann A, Leivestad T. et al The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588-595
    CrossrefPubMedSearch in Google Scholar
  • 11 Koppe L, Pelletier CC, Alix PM. et al Insulin resistance in chronic kidney disease: new lessons from experimental models. Nephrol Dial Transplant 2014; 29: 1666-1674
    CrossrefPubMedSearch in Google Scholar
  • 12 Tillmann FP, Schmitz M, Rump LC. et al Impact of low-dose steroids on HbA1c levels and development of pre-diabetes and NODAT in non-diabetic renal transplant recipients on long-term follow-up. Int Urol Nephrol 2018; 50: 771-777
    CrossrefPubMedSearch in Google Scholar
  • 13 Shimada H, Uchida J, Nishide S. et al Comparison of glucose tolerance between kidney transplant recipients and healthy controls. J Clin Med 2019; 08: 920
    CrossrefPubMedSearch in Google Scholar
  • 14 Markell M. New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. Am J Kidney Dis 2004; 43: 953-965
    CrossrefPubMedSearch in Google Scholar
  • 15 Nam JH, Mun JI, Kim SI. et al Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001; 71: 1417-1423
    CrossrefPubMedSearch in Google Scholar
  • 16 Vantyghem MC, Marcelli-Tourvielle S, Pattou F. et al Effects of non-steroid immunosuppressive drugs on insulin secretion in transplantation. Ann Endocrinol 2007; 68: 21-27
    CrossrefPubMedSearch in Google Scholar
  • 17 Oetjen E, Baun D, Beimesche S. et al Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice. Mol Pharmacol 2003; 63: 1289-1295
    CrossrefPubMedSearch in Google Scholar
  • 18 Redmon JB, Olson LK, Armstrong MB. et al Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996; 98: 2786-2793
    CrossrefPubMedSearch in Google Scholar
  • 19 Gyurus E, Kaposztas Z, Kahan BD. Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens. Transplant Proc 2011; 43: 1583-1592
    CrossrefPubMedSearch in Google Scholar
  • 20 Sommerer C, Witzke O, Lehner F. et al Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. BMC Nephrol 2018; 19: 237
    CrossrefPubMedSearch in Google Scholar
  • 21 Chang S, Jiang J. Association of body mass index and the risk of new-onset diabetes after kidney transplantation: a meta-analysis. Transplant Proc 2018; 50: 1316-1325
    CrossrefPubMedSearch in Google Scholar
  • 22 Garnier A-S, Duveau A, Planchais M. et al Serum magnesium after kidney transplantation: a systematic review. Nutrients 2018; 10: 729
    CrossrefPubMedSearch in Google Scholar
  • 23 Baid-Agrawal S, Frei U, Reinke P. et al Impaired insulin sensitivity as an underlying mechanism linking hepatitis C and posttransplant diabetes mellitus in kidney recipients. Am J Transplant 2009; 09: 2777-2784
    CrossrefPubMedSearch in Google Scholar
  • 24 Hjelmesaeth J, Sagedal S, Hartmann A. et al Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47: 1550-1556
    CrossrefPubMedSearch in Google Scholar
  • 25 Petersmann A, Müller-Wieland D, Müller UA. et al Definition, Klassifikation und Diagnostik des Diabetes mellitus. Diabetol Stoffwechs 2019; 14: S111-S118
    Thieme ConnectSearch in Google Scholar
  • 26 Mazali FC, Lalli CA, Alves-Filho G. et al Posttransplant diabetes mellitus: incidence and risk factors. Transplant Proc 2008; 40: 764-766
    CrossrefPubMedSearch in Google Scholar
  • 27 Delgado P, Diaz JM, Silva I. et al Unmasking glucose metabolism alterations in stable renal transplant recipients: a multicenter study. Clin J Am Soc Nephrol 2008; 03: 808-813
    CrossrefPubMedSearch in Google Scholar
  • 28 Mora PF. Post-transplantation diabetes mellitus. Am J Med Sci 2005; 329: 86-94
    CrossrefPubMedSearch in Google Scholar
  • 29 Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008; 03: 814-821
    CrossrefPubMedSearch in Google Scholar
  • 30 Eide IA, Halden TAS, Hartmann A. et al Associations between posttransplantation diabetes mellitus and renal graft survival. Transplantation 2017; 101: 1282-1289
    CrossrefPubMedSearch in Google Scholar
  • 31 Pascual J, Galeano C, Royuela A. et al A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation 2010; 90: 343-349
    CrossrefPubMedSearch in Google Scholar
  • 32 Chan L, Andres A, Bunnapradist S. et al Renal function and NODM in de novo renal transplant recipients treated with standard and reduced levels of tacrolimus in combination with EC-MPS. J Transplant 2012: 941640
    CrossrefPubMedSearch in Google Scholar
  • 33 Vincenti F, Friman S, Scheuermann E. et al Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 07: 1506-1514
    CrossrefPubMedSearch in Google Scholar
  • 34 Kuningas K, Driscoll J, Mair R. et al Comparing glycaemic benefits of active versus passive lifestyle intervention in kidney allograft recipients (CAVIAR): a randomised controlled trial. Transplantation 2019
    CrossrefPubMedSearch in Google Scholar
  • 35 Albersmeyer M, Gehr B, Liebl A. et al Posttransplantationsdiabetes mellitus. Der Nephrologe 2020; 15: 259-267
    CrossrefSearch in Google Scholar
  • 36 Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008; 85: 353-358
    CrossrefPubMedSearch in Google Scholar
  • 37 Hecking M, Haidinger M, Döller D. et al Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012; 23: 739-749
    CrossrefPubMedSearch in Google Scholar
  • 38 Strøm Halden TA, Åsberg A, Vik K. et al Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant 2014; 29: 926-933
    CrossrefPubMedSearch in Google Scholar
  • 39 Montero N, Oliveras L, Soler MJ. et al Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics. Clinical Kidney Journal 2022; 15: 5-13
    CrossrefPubMedSearch in Google Scholar
  • 40 Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2020; 98: S1-S115
    CrossrefPubMedSearch in Google Scholar
  • 41 Zinman B, Wanner C, Lachin JM. et al Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
    Search in Google Scholar
  • 42 Schwaiger E, Burghart L, Signorini L. et al Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant 2019; 19: 907-919
    CrossrefPubMedSearch in Google Scholar
  • 43 Halden TAS, Kvitne KE, Midtvedt K. et al Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 2019; 42: 1067-1074
    CrossrefPubMedSearch in Google Scholar
  • 44 Zinman B, Wanner C, Lachin JM. et al Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128
    Search in Google Scholar
  • 45 Wanner C, Inzucchi SE, Lachin JM. et al Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334
    Search in Google Scholar
  • 46 Mann JFE, Ørsted DD, Brown-Frandsen K. et al Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377: 839-848
    Search in Google Scholar
  • 47 Marso SP, Daniels GH, Brown-Frandsen K. et al Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322
    Search in Google Scholar